A short-term controlled trial with metformin showed that the addition of loxenatide to metformin was superior to the addition of glucagon in improving glycemic control and assessing glycemic variability with continuous glucose monitoring in patients with T2DM [14]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.